Extended funding supports Errium's development of therapeutics for chronic autoimmune diseases July 1, 2022
Series B financing at MiroBio funds development of checkpoint agonists to treat autoimmune diseases June 29, 2022
Silo in commercial evaluation license agreement for next-generation liposomes for autoimmune disease June 27, 2022
Adropin as novel therapeutic target to attenuate fibroblast activation and fibrosis in SSc June 10, 2022
New cytokine inhibitors patented by Peptinov SAS, Conservatoire National des Arts et Metiers June 7, 2022
RSS